Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Community Healthcare Trust

Medical Properties Trust

Medical Properties Trust's issues could force it to cut its big-time dividend. Johnson & Johnson backs its attractive dividend with an elite financial profile.

1 Sickly Dividend Stock to Avoid Like the Plague Right Now (and 2 Much Healthier Ones to Buy Instead)

Johnson & Johnson's proposed $8.9 billion settlement of thousands of lawsuits alleging that its talc products cause cancer faces a crucial hurdle this week as a U.S. bankruptcy judge in New Jersey considers whether or not a J&J subsidiary may resolve them by filing for bankruptcy a second time.

J&J's $8.9 billion talc settlement faces US bankruptcy test

A California man suing Johnson & Johnson told jurors on Monday how his life was upended by a cancer diagnosis that he blames on using the company's baby powder since childhood, as the first trial over the product in nearly two years neared its end.

California man tells jury of getting cancer after using J&J baby powder

McKesson

McKesson is the largest pharmaceutical distributor in the U.S. Johnson & Johnson is one of the largest healthcare companies in the world. Both stocks have steadily increased their dividends over the years.

2 Best Buffett Stocks to Buy for the Long Haul

Coca-Cola

Walgreens

Coca-Cola currently offers a 3% dividend yield. Johnson & Johnson pays a very healthy dividend.

Got $500? 3 Magnificent Dividend Stocks to Buy Without Hesitation Right Now

Apple

Adobe

Allianz SE

Amazon

BB Seguridade Participacoes SA

Blackrock Inc

Bank of Nova Scotia

Canadian Natural Resources

Salesforce

iShares Core Dividend Growth ETF

Alphabet

Goldman Sachs

JPMorgan Chase & Co

Kinder Morgan

Mastercard

Altria

Microsoft

Nasdaq

Palo Alto Networks

PayPal

Schwab US Dividend Equity ETF

Charles Schwab

A dividend income-oriented investment portfolio can provide you with an excellent source of extra income via dividend payments. I will show you how you could build an investment portfolio with my top 10 high dividend yield, dividend growth, and growth companies for the month of June. This portfolio provides you with a Weighted Average Dividend Yield [TTM] of 3.58% and has shown a Weighted Average Dividend Growth Rate [CAGR] of 11.05%.

How To Build A Dividend Portfolio With $25,000 Among June's Top 30 Stocks

Ally Financial

CVS Health

Over time, dividend-paying stocks tend to deliver better returns than non-dividend payers. CVS Health and Johnson & Johnson are healthcare conglomerates that dividend investors appreciate for different reasons.

3 Reliable Dividend Stocks to Buy Now and Hold Forever

Amgen

Boeing

Merck

The Dow Jones Industrial Average closed down 0.01%, or 4 points, spending most of the day in the red as investors digested the latest moves by central banks around the world.

Dow Jones Today: Index Flat as Investors Mull Global Rate Decisions

The global pharmaceutical industry keeps growing. J&J looks positioned to deliver growth for the long haul.

Will Johnson & Johnson Be a Trillion-Dollar Stock by 2038?

Medtronic

The global AI-in-healthcare market is on track to top $100 billion later this decade. Companies that invest in the area now could reap the rewards down the road.

AI May Transform Healthcare: 2 Top Stocks to Buy Now

Albemarle

Chevron

Newmont Mining

Tesla

With uncertainties plaguing the markets, savvy investors can find solace in resilient blue-chip stocks. These stalwarts, known for their consistent performance and resiliency, have become a haven for those looking to safeguard their investments.

7 Resilient Blue-Chip Stocks With Strong Growth Potential

Prologis

Coca-Cola and Johnson & Johnson have increased their dividend for 61 straight years. Prologis has grown its dividend at an elite pace since its IPO.

Got $1,000? 3 Elite Dividend Stocks to Buy Right Now

Caterpillar

Although these companies are from different sectors, we compare them because they have a similar P/EBIT ratio of 15x-17x.

Cross-Sector Comparison: Is Caterpillar Stock A Better Pick Over J&J?

Amazon offers a recovery story and dominance in two high-growth industries. Tesla has delivered earnings strength even during a difficult economic environment.

If I Had $1,000 to Invest Between Amazon, Johnson & Johnson, and Tesla Stocks, Here's How I'd Do It

Charles River Laboratories

One of the greatest changes in the American landscape going forward will be demographics. The Baby Boomers make up the largest generation in the country's history.

3 Long-term Healthcare Stocks to Add to Your Portfolio

Carlisle Companies

Extra Space Storage

All the “basic” investors out there are busy chasing this AI-driven rally. It's like the crypto and meme-stock messes of 2021 all over again!

3 Contrarian Buys For 15% Yields, 300% Payout Growth As AI Takes Off

MIAMI--(BUSINESS WIRE)--J&J Green Paper and Sintesa Group join forces to produce eco-friendly paper coating, replacing plastic waste.

J&J Green Paper and Sintesa Group Forge Strategic Partnership to Produce Eco-Friendly Paper Coating and Combat Global Plastic Waste

Johnson & Johnson (NYSE:JNJ ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 4:20 PM ET Company Participants Biljana Naumovic - Worldwide Vice President, Oncology Mark Wildgust - Medical Affairs Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Here we are. And welcome back from lunch, everybody.

Johnson & Johnson (JNJ) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

News for Johnson & Johnson Stock (JNJ)